spacer
home > ict > winter 2008 > regulating e-diaries
PUBLICATIONS
International Clinical Trials

Regulating e-Diaries

Secure, private and effective eDiaries deserve the trust of regulators argue Valdo Arnera and Stephen A Raymond of PHT Corporation

When most of the regulations that pertain to handling records for clinical trials were written, diaries (like most records) were completed on paper. Except for a single mention that included ‘subjects’ diaries’ under the definition of source documents (1) provided by the International Conference on Harmonisation (ICH), they were not the focus of regulations.

Therapies were approved or rejected based on clinical records, and the direct input from subjects was generally secondary to the medical assessments of their physicians. Paper questionnaires were a trusted source, but in the 1990s many regulators and scientists were sceptical of patient diaries. As eDiaries have entered the mainstream, their regulatory status has become clearer (2), and the signs suggest that regulators are laying the foundation for increasing their reliance for claims and labelling on data supplied directly from subjects in clinical trials (2,3).

BUILDING A CHAIN OF CONFIDENCE FOR ELECTRONIC RECORDS

The FDA sought to encourage “the widest possible use of electronic technology” in 1997 with Part 11 (4, Preamble). The objective was to describe what the FDA would need in order to trust electronic records as much as paper ones and avoid unduly burdensome controls. This ‘no worse than paper’ principle is embodied in the first sentence of the regulation (11.1(a)): “The regulations in this part set forth the criteria under which the agency considers electronic records ... to be trustworthy, reliable and generally equivalent to paper records...” (4).

From the design of the questionnaire or diary and its implementation on a valid device, to data transmission, storage, access, transfer and archiving, each step in the eDiary lifecycle is subject to regulations and guidelines that apply to both sponsors and sites. The eDiary providers must, therefore, prove to sponsors that their documented processes meet all the requirements for electronic records and that these standard operating procedures (SOPs) are consistently followed. In this way, the reviewers and regulators will have the information they need to establish a chain of confidence from development to final submission. By documenting compliance with the regulations, eDiary providers help study sponsors make the case that their data – and scientific conclusions – are trustworthy.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

During 20 years in the pharmaceutical industry, Dr Valdo Arnera has held positions ranging from Clinical Research Physician to Vice President of Medical Affairs. He founded PHT’s European affiliate in January 2001, and is active in DIA. Prior to PHT, he established the first European central clinical laboratory for clinical trials. Valdo received his French State Doctor’s Degree in Medicine from the University of Clermont-Ferrand I.

Dr Stephen A Raymond pioneered mobile eDiary and eSource data capture systems and has worked with regulatory authorities and CDISC to clarify the regulatory status of eSource devices since founding PHT in 1994. He received his PhD in Neurophysiology from MIT, and has held faculty appointments in Electrical Engineering, Computer Science, Neuroscience and Anaesthesia at MIT and Harvard Medical Schools.

spacer
Dr Valdo Arnera
spacer
spacer
spacer
Dr Stephen A Raymond
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo awarded with the prestigious Cargo Airline of the Year 2019 prize by the global logistics industry

 Maintaining its upward trend, Turkish Cargo was granted with the ‘Cargo Airline of the Year 2019’ award, called as the Oscar of the global logistics industry, by the global air cargo sector readers of the Air Cargo News magazine.
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

 
Industry Events

Clinical Trial Supply Global Forum

20-22 May 2019, Brussels, Belgium

You can’t get a drug to market without a clinical trial. You can’t run a clinical trial without product supply. We understand that your role is critical in ensuring the on time and efficient development of the next life saving drug and we know that this makes your time precious. In 2019 we have condensed everything you need to advance your Clinical Trial Supply into three jam packed days. The industry's most interactive and solution focused CTS forum features deep dive workshops, live polls, panel debates, round table discussions and exclusive key note case studies to ensure that you leave with the industry's best solutions and strategies to transform your clinical trial supply. If there is ONE Clinical Trial Supply conference that you attend in 2019, make sure that it is this one.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement